Cargando…

Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy

Diabetic retinopathy (DR) is the most frequent microvascular retinal complication of diabetic patients, contributing to loss of vision. Recently, retinal neuroinflammation and neurodegeneration have emerged as key players in DR progression, and therefore, this review examines the neuroinflammatory m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepre, Caterina Claudia, Russo, Marina, Trotta, Maria Consiglia, Petrillo, Francesco, D’Agostino, Fabiana Anna, Gaudino, Gennaro, D’Amico, Giovanbattista, Campitiello, Maria Rosaria, Crisci, Erminia, Nicoletti, Maddalena, Gesualdo, Carlo, Simonelli, Francesca, D’Amico, Michele, Hermenean, Anca, Rossi, Settimio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253913/
https://www.ncbi.nlm.nih.gov/pubmed/37298672
http://dx.doi.org/10.3390/ijms24119721
_version_ 1785056519486701568
author Lepre, Caterina Claudia
Russo, Marina
Trotta, Maria Consiglia
Petrillo, Francesco
D’Agostino, Fabiana Anna
Gaudino, Gennaro
D’Amico, Giovanbattista
Campitiello, Maria Rosaria
Crisci, Erminia
Nicoletti, Maddalena
Gesualdo, Carlo
Simonelli, Francesca
D’Amico, Michele
Hermenean, Anca
Rossi, Settimio
author_facet Lepre, Caterina Claudia
Russo, Marina
Trotta, Maria Consiglia
Petrillo, Francesco
D’Agostino, Fabiana Anna
Gaudino, Gennaro
D’Amico, Giovanbattista
Campitiello, Maria Rosaria
Crisci, Erminia
Nicoletti, Maddalena
Gesualdo, Carlo
Simonelli, Francesca
D’Amico, Michele
Hermenean, Anca
Rossi, Settimio
author_sort Lepre, Caterina Claudia
collection PubMed
description Diabetic retinopathy (DR) is the most frequent microvascular retinal complication of diabetic patients, contributing to loss of vision. Recently, retinal neuroinflammation and neurodegeneration have emerged as key players in DR progression, and therefore, this review examines the neuroinflammatory molecular basis of DR. We focus on four important aspects of retinal neuroinflammation: (i) the exacerbation of endoplasmic reticulum (ER) stress; (ii) the activation of the NLRP3 inflammasome; (iii) the role of galectins; and (iv) the activation of purinergic 2X7 receptor (P2X7R). Moreover, this review proposes the selective inhibition of galectins and the P2X7R as a potential pharmacological approach to prevent the progression of DR.
format Online
Article
Text
id pubmed-10253913
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102539132023-06-10 Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy Lepre, Caterina Claudia Russo, Marina Trotta, Maria Consiglia Petrillo, Francesco D’Agostino, Fabiana Anna Gaudino, Gennaro D’Amico, Giovanbattista Campitiello, Maria Rosaria Crisci, Erminia Nicoletti, Maddalena Gesualdo, Carlo Simonelli, Francesca D’Amico, Michele Hermenean, Anca Rossi, Settimio Int J Mol Sci Review Diabetic retinopathy (DR) is the most frequent microvascular retinal complication of diabetic patients, contributing to loss of vision. Recently, retinal neuroinflammation and neurodegeneration have emerged as key players in DR progression, and therefore, this review examines the neuroinflammatory molecular basis of DR. We focus on four important aspects of retinal neuroinflammation: (i) the exacerbation of endoplasmic reticulum (ER) stress; (ii) the activation of the NLRP3 inflammasome; (iii) the role of galectins; and (iv) the activation of purinergic 2X7 receptor (P2X7R). Moreover, this review proposes the selective inhibition of galectins and the P2X7R as a potential pharmacological approach to prevent the progression of DR. MDPI 2023-06-03 /pmc/articles/PMC10253913/ /pubmed/37298672 http://dx.doi.org/10.3390/ijms24119721 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lepre, Caterina Claudia
Russo, Marina
Trotta, Maria Consiglia
Petrillo, Francesco
D’Agostino, Fabiana Anna
Gaudino, Gennaro
D’Amico, Giovanbattista
Campitiello, Maria Rosaria
Crisci, Erminia
Nicoletti, Maddalena
Gesualdo, Carlo
Simonelli, Francesca
D’Amico, Michele
Hermenean, Anca
Rossi, Settimio
Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy
title Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy
title_full Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy
title_fullStr Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy
title_full_unstemmed Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy
title_short Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy
title_sort inhibition of galectins and the p2x7 purinergic receptor as a therapeutic approach in the neurovascular inflammation of diabetic retinopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253913/
https://www.ncbi.nlm.nih.gov/pubmed/37298672
http://dx.doi.org/10.3390/ijms24119721
work_keys_str_mv AT leprecaterinaclaudia inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT russomarina inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT trottamariaconsiglia inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT petrillofrancesco inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT dagostinofabianaanna inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT gaudinogennaro inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT damicogiovanbattista inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT campitiellomariarosaria inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT criscierminia inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT nicolettimaddalena inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT gesualdocarlo inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT simonellifrancesca inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT damicomichele inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT hermeneananca inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy
AT rossisettimio inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy